[go: up one dir, main page]

SE0203137D0 - Drug target in cancer therapy - Google Patents

Drug target in cancer therapy

Info

Publication number
SE0203137D0
SE0203137D0 SE0203137A SE0203137A SE0203137D0 SE 0203137 D0 SE0203137 D0 SE 0203137D0 SE 0203137 A SE0203137 A SE 0203137A SE 0203137 A SE0203137 A SE 0203137A SE 0203137 D0 SE0203137 D0 SE 0203137D0
Authority
SE
Sweden
Prior art keywords
cancer therapy
drug target
relates
cyp2w1
therapeutic agents
Prior art date
Application number
SE0203137A
Other languages
English (en)
Swedish (sv)
Inventor
Magnus Ingelman-Sundberg
Maria Karlgren
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE0203137A priority Critical patent/SE0203137D0/xx
Publication of SE0203137D0 publication Critical patent/SE0203137D0/xx
Priority to US10/532,014 priority patent/US20060166912A1/en
Priority to AT03754349T priority patent/ATE435027T1/de
Priority to AU2003272180A priority patent/AU2003272180A1/en
Priority to CNA2003801055321A priority patent/CN1753689A/zh
Priority to PCT/SE2003/001652 priority patent/WO2004037282A1/en
Priority to EP03754349A priority patent/EP1565208B1/en
Priority to DE60328218T priority patent/DE60328218D1/de
Priority to US12/046,136 priority patent/US20080242637A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/90245Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0203137A 2002-10-24 2002-10-24 Drug target in cancer therapy SE0203137D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0203137A SE0203137D0 (sv) 2002-10-24 2002-10-24 Drug target in cancer therapy
US10/532,014 US20060166912A1 (en) 2002-10-24 2003-10-24 Use of cytochrome p450 enzyme cyp2w1 as a drug target for cancer theraphy
AT03754349T ATE435027T1 (de) 2002-10-24 2003-10-24 Einsatz des cytochrom p450-enzyms cyp2wi als zielmolekül für wirkstoffe bei der krebstherapie
AU2003272180A AU2003272180A1 (en) 2002-10-24 2003-10-24 The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy
CNA2003801055321A CN1753689A (zh) 2002-10-24 2003-10-24 细胞色素p450酶cyp2w1作为药物目标用于癌症治疗的用途
PCT/SE2003/001652 WO2004037282A1 (en) 2002-10-24 2003-10-24 The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy
EP03754349A EP1565208B1 (en) 2002-10-24 2003-10-24 The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy
DE60328218T DE60328218D1 (de) 2002-10-24 2003-10-24 Einsatz des cytochrom p450-enzyms cyp2wi als zielmolekül für wirkstoffe bei der krebstherapie
US12/046,136 US20080242637A1 (en) 2002-10-24 2008-03-11 Use of Cytochrome P450 Enzyme CYP2WI as a Drug Target for Cancer Therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203137A SE0203137D0 (sv) 2002-10-24 2002-10-24 Drug target in cancer therapy

Publications (1)

Publication Number Publication Date
SE0203137D0 true SE0203137D0 (sv) 2002-10-24

Family

ID=20289352

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203137A SE0203137D0 (sv) 2002-10-24 2002-10-24 Drug target in cancer therapy

Country Status (8)

Country Link
US (2) US20060166912A1 (xx)
EP (1) EP1565208B1 (xx)
CN (1) CN1753689A (xx)
AT (1) ATE435027T1 (xx)
AU (1) AU2003272180A1 (xx)
DE (1) DE60328218D1 (xx)
SE (1) SE0203137D0 (xx)
WO (1) WO2004037282A1 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1907420T3 (pl) * 2005-07-21 2017-09-29 Modiquest B.V. Pleksyna D1 jako obiekt docelowy do diagnozowania i leczenia guza
KR20240161207A (ko) 2015-05-06 2024-11-12 이매틱스 바이오테크놀로지스 게엠베하 결장직장 암종(crc) 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드와 이의 골격의 조합
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof

Also Published As

Publication number Publication date
US20080242637A1 (en) 2008-10-02
CN1753689A (zh) 2006-03-29
AU2003272180A1 (en) 2004-05-13
EP1565208A1 (en) 2005-08-24
WO2004037282A1 (en) 2004-05-06
EP1565208B1 (en) 2009-07-01
ATE435027T1 (de) 2009-07-15
DE60328218D1 (de) 2009-08-13
US20060166912A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
PL1742644T3 (pl) Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
LUC00011I2 (xx)
MX2007003907A (es) Agentes terapeuticos con toxicidad reducida.
EP2061456A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME
LU92203I9 (xx)
MY144632A (en) Cytotoxic agents comprising new taxanes
WO2004094614A3 (en) Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
SE0203137D0 (sv) Drug target in cancer therapy
WO2006050498A3 (en) Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2003026696A1 (fr) Procede permettant de maitriser la proliferation de cellules cancereuses et la mort cellulaire
ATE490981T1 (de) Criptospezifische antikörper